相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design strategies to address kinetics of drug binding and residence time
Kevin P. Cusack et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models
Georges Vauquelin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor
Dong Guo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands
David C. Swinney et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands
Georges Vauquelin et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2014)
Drug-Target Residence Time-A Case for G Protein-Coupled Receptors
Dong Guo et al.
MEDICINAL RESEARCH REVIEWS (2014)
Observed Drug-Receptor Association Rates Are Governed by Membrane Affinity: The Importance of Establishing Micro-Pharmacokinetic/Pharmacodynamic Relationships at the β2-Adrenoceptor
David A. Sykes et al.
MOLECULAR PHARMACOLOGY (2014)
Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands
Georges Vauquelin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
D. C. Swinney
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Pharmacokinetics and the drug-target residence time concept
Goran Dahl et al.
DRUG DISCOVERY TODAY (2013)
Hybrid Bombesin Analogues: Combining an Agonist and an Antagonist in Defined Distances for Optimized Tumor Targeting
Carsten Kroll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels
Ning Yin et al.
MOLECULAR BIOSYSTEMS (2013)
Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time
Georges Vauquelin
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2013)
Bridging the gap: bitopic ligands of G-protein-coupled receptors
J. Robert Lane et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein-Coupled Receptors
Celine Valant et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting ß2-adrenoceptor agonists
David A. Sykes et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Target-drug interactions: first principles and their application to drug discovery
Sara Nunez et al.
DRUG DISCOVERY TODAY (2012)
Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems
Georges Vauquelin et al.
EXPERT OPINION ON DRUG DISCOVERY (2012)
Crystal Structure of a Lipid G Protein-Coupled Receptor
Michael A. Hanson et al.
SCIENCE (2012)
Conformational adaptation in drug-target interactions and residence time
Robert A. Copeland
FUTURE MEDICINAL CHEMISTRY (2011)
Comparative Biophysical Studies of Sartan Class Drug Molecules Losartan and Candesartan (CV-11974) with Membrane Bilayers
Charalambos Fotakis et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2011)
How were new medicines discovered?
David C. Swinney et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Physics of protein-DNA interactions: mechanisms of facilitated target search
Anatoly B. Kolomeisky
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2011)
Pathway and mechanism of drug binding to G-protein-coupled receptors
Ron O. Dror et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor
S. Patel et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2011)
Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach
A. Packeu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Rational design of dualsteric GPCR ligands: quests and promise
Klaus Mohr et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action
Georges Vauquelin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Drug-target residence time: critical information for lead optimization
Hao Lu et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time
Georges Vauquelin
EXPERT OPINION ON DRUG DISCOVERY (2010)
The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety
Robert A. Copeland
EXPERT OPINION ON DRUG DISCOVERY (2010)
A Lipid Pathway for Ligand Binding Is Necessary for a Cannabinoid G Protein-coupled Receptor
Dow P. Hurst et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Molecular mechanisms for the persistent bronchodilatory effect of the beta(2)-adrenoceptor agonist salmeterol
A. Szczuka et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Affinity and Avidity in Antibody-Based Tumor Targeting
Stephen I. Rudnick et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism
I. Van Liefde et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Ligands, their receptors and ... plasma membranes
G. Vauquelin et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
OPINION Cellular assays as portals to seven-transmembrane receptor-based drug discovery
Terry P. Kenakin
NATURE REVIEWS DRUG DISCOVERY (2009)
A Ligand Channel through the G Protein Coupled Receptor Opsin
Peter W. Hildebrand et al.
PLOS ONE (2009)
Residence time of receptor-ligand complexes and its effect on biological function
Peter J. Tummino et al.
BIOCHEMISTRY (2008)
Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor
M. T. Le et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Allosteric modulators of class B G-protein-coupled receptors
Sam R. J. Hoare
CURRENT NEUROPHARMACOLOGY (2007)
Determining the potency and molecular mechanism of action of insurmountable antagonists
Terry Kenakin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Can binding kinetics translate to a clinically differentiated drug? From theory to practice
David C. Swinney
LETTERS IN DRUG DESIGN & DISCOVERY (2006)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Slow antagonist dissociation and long-lasting in vivo receptor protection
Georges Vauquelin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the membrane catalysis model
MARB Castanho et al.
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS (2006)
Diffusion delays and unstirred layer effects at monolayer cultures of chinese hamster ovary cells - Radioligand binding, confocal microscopy, and mathematical simulations
CE Spivak et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2006)
Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism
M Castro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Effect of saponin and filipin on antagonist binding to AT1 receptors in intact cells
I Verheijen et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Effects of the geometry of the immunological synapse on the delivery of effector molecules
D Coombs et al.
BIOPHYSICAL JOURNAL (2004)
Biochemical mechanisms of drug action: what does it take for success?
DC Swinney
NATURE REVIEWS DRUG DISCOVERY (2004)
Receptor-mediated biological responses are prolonged using hydrophobized ligands
M De Cuyper et al.
BIOSENSORS & BIOELECTRONICS (2004)
Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M-1 receptors
J Jakubik et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Probing the mechanism of drug/lipid membrane interactions using Biacore
YN Abdiche et al.
ANALYTICAL BIOCHEMISTRY (2004)
QSAR and the rational design of long-acting dual D2-receptor/β2-adrenoceptor agonists
RP Austin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Ligand-selective receptor conformations revisited: the promise and the problem
T Kenakin
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology
RR Neubig et al.
PHARMACOLOGICAL REVIEWS (2003)
Models and methods for studying insurmountable antagonism
G Vauquelin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
G protein-coupled receptor allosterism and complexing
A Christopoulos et al.
PHARMACOLOGICAL REVIEWS (2002)
Distinct binding properties of the AT1 receptor antagonist [3H]candesartan to intact cells and membrane preparations
FLP Fierens et al.
BIOCHEMICAL PHARMACOLOGY (2002)
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists
G Vauquelin et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Design and application of diabodies, triabodies and tetrabodies for cancer targeting
A Todorovska et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
分享论文
